Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Dr. Hudis on the Link Between Obesity and Cancer

      March 3, 2015
      By Clifford A. Hudis, MD
      Video

      Clifford A. Hudis, MD, chief, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, professor of medicine, Weill Cornell Medical College, discusses the link between obesity and cancer.

      Clifford A. Hudis, MD, chief, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, professor of medicine, Weill Cornell Medical College, discusses the link between obesity and cancer.

      Hudis says the problem of obesity in the United States is a relatively new issue and has profound medical consequences. Many people know that obesity can lead to arthritis, diabetes and hypertension, but obesity can also cause pancreatitis, gallstones, reflux esophagitis and other ailments including cancer, Hudis says.

      Researchers have known that obesity was associated with some specific cancers, such as uterine cancer and breast cancer but they are now discovering that obesity is also associated with colon cancer and high-grade prostate cancers.

      Hudis says the reason obesity is associated with cancer is the biochemical reactions that take place when a patient is obese. There are inflammatory cellular structures within the fat tissue that produce inflammatory mediators, which activate aromatase. The activation of aromatase is associate with both breast cancer and endometrial cancer, Hudis says.​

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Image of a woman wearing a patterned shirt in front of a dark blue background
      Photo of a woman wearing a blazer in front of an Oncology Nursing News backdrop
      3 experts in this video
      3 experts in this video
      Photo of a white man with curly hair and in front of a blue Oncology Nursing News backdrop
      Related Content

      Anatomical image of a person with a breast tumor

      T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

      Tim Cortese
      June 11th 2025
      Article

      T-DXd led to an ORR of 59.4% vs 33.9% with chemo, regardless of biomarker status, in HR+, HER2-low metastatic breast cancer, per DESTINY-Breast06.


      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Lindsay Fischer
      October 2nd 2023
      Podcast

      Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.


      AI-generated graphic of cancer cells

      T-DXd Rechallenge Tolerable Post Grade 1 ILD in Breast, Solid Tumors

      Chris Ryan
      June 2nd 2025
      Article

      Seventy-three percent of patients with breast and other solid tumors did not experience ILD recurrence when rechallenged with trastuzumab.


      The Vitals

      Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

      Lindsay Fischer
      January 16th 2023
      Podcast

      Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.


      Line illustration of a breast

      Sacituzumab Govitecan/Pembrolizumab Backed as New SOC in PD-L1+ TNBC

      Kristi Rosa
      May 31st 2025
      Article

      Sacituzumab govitecan/pembrolizumab in the first line lengthened PFS vs chemotherapy/pembrolizumab in PD-L1+ metastatic triple-negative breast cancer.


      Anatomical rendering of a breast with a tumor

      Vepdegestrant Increases PFS in ESR1-Mutated ER+/HER2- Breast Cancer

      Caroline Seymour
      May 31st 2025
      Article

      Patients with ESR1-mutated, ER-positive, HER2-negative, advanced breast cancer experienced an increase in PFS with vepdegestrant compared with fulvestrant.

      Related Content

      Anatomical image of a person with a breast tumor

      T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

      Tim Cortese
      June 11th 2025
      Article

      T-DXd led to an ORR of 59.4% vs 33.9% with chemo, regardless of biomarker status, in HR+, HER2-low metastatic breast cancer, per DESTINY-Breast06.


      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Lindsay Fischer
      October 2nd 2023
      Podcast

      Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.


      AI-generated graphic of cancer cells

      T-DXd Rechallenge Tolerable Post Grade 1 ILD in Breast, Solid Tumors

      Chris Ryan
      June 2nd 2025
      Article

      Seventy-three percent of patients with breast and other solid tumors did not experience ILD recurrence when rechallenged with trastuzumab.


      The Vitals

      Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

      Lindsay Fischer
      January 16th 2023
      Podcast

      Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.


      Line illustration of a breast

      Sacituzumab Govitecan/Pembrolizumab Backed as New SOC in PD-L1+ TNBC

      Kristi Rosa
      May 31st 2025
      Article

      Sacituzumab govitecan/pembrolizumab in the first line lengthened PFS vs chemotherapy/pembrolizumab in PD-L1+ metastatic triple-negative breast cancer.


      Anatomical rendering of a breast with a tumor

      Vepdegestrant Increases PFS in ESR1-Mutated ER+/HER2- Breast Cancer

      Caroline Seymour
      May 31st 2025
      Article

      Patients with ESR1-mutated, ER-positive, HER2-negative, advanced breast cancer experienced an increase in PFS with vepdegestrant compared with fulvestrant.

      Latest Conference Coverage

      Relacorilant Combo Boosts PFS in Resistant Ovarian Cancer

      Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care

      T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

      AI Tool May Predict Response, Resistance in Advanced RCC

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.